Somerville, MA, United States of America

Afrand Kamali Sarvestani

USPTO Granted Patents = 2 

Average Co-Inventor Count = 18.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2023

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Afrand Kamali Sarvestani: Innovator in Metabolic Disorder Treatments

Introduction

Afrand Kamali Sarvestani is a notable inventor based in Somerville, MA (US). He has made significant contributions to the field of medical treatments, particularly focusing on metabolic disorders and nonalcoholic fatty liver disease. With a total of two patents to his name, his work is paving the way for innovative solutions in healthcare.

Latest Patents

Afrand's latest patents include active agents and methods for their use in treating metabolic disorders and nonalcoholic fatty liver disease. These patents disclose active agents, compositions containing them, unit dosage forms, and methods for their application. His research aims to provide effective treatments for individuals suffering from these conditions, enhancing their quality of life.

Career Highlights

Afrand Kamali Sarvestani is currently associated with Flagship Pioneering Innovations V, Inc. His role in this innovative company allows him to collaborate with other leading experts in the field. His dedication to research and development has positioned him as a key player in the medical innovation landscape.

Collaborations

Some of Afrand's notable coworkers include Steven John Taylor and John Robert Proudfoot. Their collective expertise contributes to the advancement of research and the development of new therapeutic methods.

Conclusion

Afrand Kamali Sarvestani's work in the treatment of metabolic disorders and nonalcoholic fatty liver disease exemplifies the impact of innovation in healthcare. His patents and collaborations reflect a commitment to improving patient outcomes through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…